nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ABCB1—kidney cancer	0.192	1	CbGaD
Maprotiline—ORM1—Erlotinib—kidney cancer	0.0773	0.155	CbGbCtD
Maprotiline—ABCB1—Temsirolimus—kidney cancer	0.0454	0.0908	CbGbCtD
Maprotiline—HTR2C—Sorafenib—kidney cancer	0.0435	0.087	CbGbCtD
Maprotiline—CYP2D6—Temsirolimus—kidney cancer	0.0427	0.0856	CbGbCtD
Maprotiline—CYP1A2—Pazopanib—kidney cancer	0.0273	0.0546	CbGbCtD
Maprotiline—ABCB1—Pazopanib—kidney cancer	0.0238	0.0477	CbGbCtD
Maprotiline—CYP2D6—Pazopanib—kidney cancer	0.0225	0.045	CbGbCtD
Maprotiline—ABCB1—Dactinomycin—kidney cancer	0.0218	0.0436	CbGbCtD
Maprotiline—CYP1A2—Erlotinib—kidney cancer	0.0194	0.0389	CbGbCtD
Maprotiline—ABCB1—Gemcitabine—kidney cancer	0.0172	0.0345	CbGbCtD
Maprotiline—ABCB1—Erlotinib—kidney cancer	0.017	0.034	CbGbCtD
Maprotiline—CYP2D6—Erlotinib—kidney cancer	0.016	0.0321	CbGbCtD
Maprotiline—CYP1A2—Sorafenib—kidney cancer	0.0158	0.0317	CbGbCtD
Maprotiline—ABCB1—Paclitaxel—kidney cancer	0.0156	0.0312	CbGbCtD
Maprotiline—ABCB1—Sorafenib—kidney cancer	0.0138	0.0277	CbGbCtD
Maprotiline—ABCB1—Vinblastine—kidney cancer	0.0137	0.0273	CbGbCtD
Maprotiline—ABCB1—Vincristine—kidney cancer	0.0134	0.0269	CbGbCtD
Maprotiline—CYP2D6—Sorafenib—kidney cancer	0.013	0.0261	CbGbCtD
Maprotiline—CYP2D6—Vinblastine—kidney cancer	0.0129	0.0258	CbGbCtD
Maprotiline—ABCB1—Sunitinib—kidney cancer	0.0112	0.0224	CbGbCtD
Maprotiline—ABCB1—Doxorubicin—kidney cancer	0.00839	0.0168	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—kidney cancer	0.0079	0.0158	CbGbCtD
Maprotiline—CHRM3—ureter—kidney cancer	0.00752	0.401	CbGeAlD
Maprotiline—Dimetacrine—ACHE—kidney cancer	0.00186	0.547	CrCbGaD
Maprotiline—CYP1A2—urine—kidney cancer	0.00186	0.099	CbGeAlD
Maprotiline—HTR2A—urine—kidney cancer	0.00145	0.0774	CbGeAlD
Maprotiline—CYP2D6—urine—kidney cancer	0.00132	0.0705	CbGeAlD
Maprotiline—Sertraline—ABCB1—kidney cancer	0.00065	0.192	CrCbGaD
Maprotiline—CHRM3—renal system—kidney cancer	0.000598	0.0319	CbGeAlD
Maprotiline—CHRM3—kidney—kidney cancer	0.000578	0.0309	CbGeAlD
Maprotiline—HTR7—renal system—kidney cancer	0.000569	0.0304	CbGeAlD
Maprotiline—HTR7—kidney—kidney cancer	0.00055	0.0294	CbGeAlD
Maprotiline—SLC6A2—gonad—kidney cancer	0.000529	0.0283	CbGeAlD
Maprotiline—HTR7—gonad—kidney cancer	0.00051	0.0272	CbGeAlD
Maprotiline—CYP1A2—renal system—kidney cancer	0.000454	0.0242	CbGeAlD
Maprotiline—Protriptyline—ABCB1—kidney cancer	0.000373	0.11	CrCbGaD
Maprotiline—HTR2A—renal system—kidney cancer	0.000355	0.0189	CbGeAlD
Maprotiline—HTR2A—kidney—kidney cancer	0.000343	0.0183	CbGeAlD
Maprotiline—CYP2D6—renal system—kidney cancer	0.000323	0.0173	CbGeAlD
Maprotiline—HTR2A—gonad—kidney cancer	0.000318	0.017	CbGeAlD
Maprotiline—CYP2D6—kidney—kidney cancer	0.000313	0.0167	CbGeAlD
Maprotiline—Nortriptyline—PTGS1—kidney cancer	0.000294	0.0868	CrCbGaD
Maprotiline—ABCB1—nephron tubule—kidney cancer	0.000256	0.0137	CbGeAlD
Maprotiline—ABCB1—renal system—kidney cancer	0.000233	0.0124	CbGeAlD
Maprotiline—ABCB1—kidney—kidney cancer	0.000225	0.012	CbGeAlD
Maprotiline—ABCB1—cortex of kidney—kidney cancer	0.000219	0.0117	CbGeAlD
Maprotiline—ABCB1—gonad—kidney cancer	0.000209	0.0111	CbGeAlD
Maprotiline—Menopausal symptoms—Doxorubicin—kidney cancer	0.000177	0.000731	CcSEcCtD
Maprotiline—Insomnia—Vincristine—kidney cancer	0.000177	0.00073	CcSEcCtD
Maprotiline—Vomiting—Vinblastine—kidney cancer	0.000177	0.000729	CcSEcCtD
Maprotiline—Dizziness—Erlotinib—kidney cancer	0.000177	0.000729	CcSEcCtD
Maprotiline—Vomiting—Everolimus—kidney cancer	0.000176	0.000726	CcSEcCtD
Maprotiline—Urethral disorder—Capecitabine—kidney cancer	0.000176	0.000726	CcSEcCtD
Maprotiline—Paraesthesia—Vincristine—kidney cancer	0.000176	0.000724	CcSEcCtD
Maprotiline—Agitation—Paclitaxel—kidney cancer	0.000175	0.000722	CcSEcCtD
Maprotiline—Rash—Everolimus—kidney cancer	0.000175	0.00072	CcSEcCtD
Maprotiline—Dermatitis—Everolimus—kidney cancer	0.000175	0.000719	CcSEcCtD
Maprotiline—Headache—Vinblastine—kidney cancer	0.000174	0.000718	CcSEcCtD
Maprotiline—Purpura—Doxorubicin—kidney cancer	0.000174	0.000716	CcSEcCtD
Maprotiline—Headache—Everolimus—kidney cancer	0.000174	0.000715	CcSEcCtD
Maprotiline—Hypotension—Gemcitabine—kidney cancer	0.000174	0.000715	CcSEcCtD
Maprotiline—Abdominal pain—Dactinomycin—kidney cancer	0.000173	0.000714	CcSEcCtD
Maprotiline—Body temperature increased—Dactinomycin—kidney cancer	0.000173	0.000714	CcSEcCtD
Maprotiline—Asthenia—Sorafenib—kidney cancer	0.000173	0.000711	CcSEcCtD
Maprotiline—Syncope—Paclitaxel—kidney cancer	0.000171	0.000704	CcSEcCtD
Maprotiline—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000171	0.000704	CcSEcCtD
Maprotiline—Leukopenia—Paclitaxel—kidney cancer	0.000171	0.000703	CcSEcCtD
Maprotiline—Pruritus—Sorafenib—kidney cancer	0.00017	0.000701	CcSEcCtD
Maprotiline—Vomiting—Erlotinib—kidney cancer	0.00017	0.000701	CcSEcCtD
Maprotiline—Erythema multiforme—Capecitabine—kidney cancer	0.00017	0.0007	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Vincristine—kidney cancer	0.000169	0.000697	CcSEcCtD
Maprotiline—Fatigue—Vincristine—kidney cancer	0.000169	0.000696	CcSEcCtD
Maprotiline—Rash—Erlotinib—kidney cancer	0.000169	0.000695	CcSEcCtD
Maprotiline—Dermatitis—Erlotinib—kidney cancer	0.000168	0.000694	CcSEcCtD
Maprotiline—Palpitations—Paclitaxel—kidney cancer	0.000168	0.000694	CcSEcCtD
Maprotiline—Insomnia—Gemcitabine—kidney cancer	0.000168	0.000692	CcSEcCtD
Maprotiline—Eye disorder—Capecitabine—kidney cancer	0.000168	0.000692	CcSEcCtD
Maprotiline—Headache—Erlotinib—kidney cancer	0.000167	0.00069	CcSEcCtD
Maprotiline—Tinnitus—Capecitabine—kidney cancer	0.000167	0.00069	CcSEcCtD
Maprotiline—Loss of consciousness—Paclitaxel—kidney cancer	0.000167	0.00069	CcSEcCtD
Maprotiline—Constipation—Vincristine—kidney cancer	0.000167	0.00069	CcSEcCtD
Maprotiline—Osteoarthritis—Doxorubicin—kidney cancer	0.000167	0.00069	CcSEcCtD
Maprotiline—Paraesthesia—Gemcitabine—kidney cancer	0.000167	0.000687	CcSEcCtD
Maprotiline—Cardiac disorder—Capecitabine—kidney cancer	0.000167	0.000687	CcSEcCtD
Maprotiline—Flushing—Capecitabine—kidney cancer	0.000167	0.000687	CcSEcCtD
Maprotiline—Asthenia—Sunitinib—kidney cancer	0.000166	0.000684	CcSEcCtD
Maprotiline—Nausea—Vinblastine—kidney cancer	0.000165	0.000681	CcSEcCtD
Maprotiline—Somnolence—Gemcitabine—kidney cancer	0.000165	0.00068	CcSEcCtD
Maprotiline—Convulsion—Paclitaxel—kidney cancer	0.000165	0.00068	CcSEcCtD
Maprotiline—Nausea—Everolimus—kidney cancer	0.000165	0.000678	CcSEcCtD
Maprotiline—Diarrhoea—Sorafenib—kidney cancer	0.000165	0.000678	CcSEcCtD
Maprotiline—Hypertension—Paclitaxel—kidney cancer	0.000164	0.000678	CcSEcCtD
Maprotiline—Pruritus—Sunitinib—kidney cancer	0.000164	0.000675	CcSEcCtD
Maprotiline—Angiopathy—Capecitabine—kidney cancer	0.000163	0.000672	CcSEcCtD
Maprotiline—Mediastinal disorder—Capecitabine—kidney cancer	0.000162	0.000667	CcSEcCtD
Maprotiline—Anxiety—Paclitaxel—kidney cancer	0.000162	0.000666	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000161	0.000664	CcSEcCtD
Maprotiline—Arrhythmia—Capecitabine—kidney cancer	0.00016	0.000661	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00016	0.000661	CcSEcCtD
Maprotiline—Fatigue—Gemcitabine—kidney cancer	0.00016	0.00066	CcSEcCtD
Maprotiline—Gastrointestinal pain—Vincristine—kidney cancer	0.00016	0.00066	CcSEcCtD
Maprotiline—Dizziness—Sorafenib—kidney cancer	0.000159	0.000656	CcSEcCtD
Maprotiline—Constipation—Gemcitabine—kidney cancer	0.000159	0.000655	CcSEcCtD
Maprotiline—Nausea—Erlotinib—kidney cancer	0.000159	0.000654	CcSEcCtD
Maprotiline—Alopecia—Capecitabine—kidney cancer	0.000159	0.000654	CcSEcCtD
Maprotiline—Dry mouth—Paclitaxel—kidney cancer	0.000159	0.000654	CcSEcCtD
Maprotiline—Diarrhoea—Sunitinib—kidney cancer	0.000158	0.000653	CcSEcCtD
Maprotiline—Ataxia—Doxorubicin—kidney cancer	0.000157	0.000649	CcSEcCtD
Maprotiline—Asthenia—Dactinomycin—kidney cancer	0.000157	0.000648	CcSEcCtD
Maprotiline—Confusional state—Paclitaxel—kidney cancer	0.000157	0.000646	CcSEcCtD
Maprotiline—Malnutrition—Capecitabine—kidney cancer	0.000156	0.000644	CcSEcCtD
Maprotiline—Oedema—Paclitaxel—kidney cancer	0.000155	0.000641	CcSEcCtD
Maprotiline—Body temperature increased—Vincristine—kidney cancer	0.000155	0.000638	CcSEcCtD
Maprotiline—Abdominal pain—Vincristine—kidney cancer	0.000155	0.000638	CcSEcCtD
Maprotiline—Liver function test abnormal—Doxorubicin—kidney cancer	0.000154	0.000637	CcSEcCtD
Maprotiline—Infection—Paclitaxel—kidney cancer	0.000154	0.000637	CcSEcCtD
Maprotiline—Dysgeusia—Capecitabine—kidney cancer	0.000153	0.000631	CcSEcCtD
Maprotiline—Dizziness—Sunitinib—kidney cancer	0.000153	0.000631	CcSEcCtD
Maprotiline—Feeling abnormal—Gemcitabine—kidney cancer	0.000153	0.000631	CcSEcCtD
Maprotiline—Shock—Paclitaxel—kidney cancer	0.000153	0.00063	CcSEcCtD
Maprotiline—Vomiting—Sorafenib—kidney cancer	0.000153	0.00063	CcSEcCtD
Maprotiline—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000153	0.00063	CcSEcCtD
Maprotiline—Nervous system disorder—Paclitaxel—kidney cancer	0.000152	0.000628	CcSEcCtD
Maprotiline—Thrombocytopenia—Paclitaxel—kidney cancer	0.000152	0.000627	CcSEcCtD
Maprotiline—Tachycardia—Paclitaxel—kidney cancer	0.000152	0.000625	CcSEcCtD
Maprotiline—Rash—Sorafenib—kidney cancer	0.000152	0.000625	CcSEcCtD
Maprotiline—Dermatitis—Sorafenib—kidney cancer	0.000152	0.000624	CcSEcCtD
Maprotiline—Breast disorder—Doxorubicin—kidney cancer	0.000151	0.000623	CcSEcCtD
Maprotiline—Skin disorder—Paclitaxel—kidney cancer	0.000151	0.000622	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000151	0.000621	CcSEcCtD
Maprotiline—Headache—Sorafenib—kidney cancer	0.000151	0.000621	CcSEcCtD
Maprotiline—Hyperhidrosis—Paclitaxel—kidney cancer	0.00015	0.000619	CcSEcCtD
Maprotiline—Diarrhoea—Dactinomycin—kidney cancer	0.00015	0.000618	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—kidney cancer	0.000148	0.000608	CcSEcCtD
Maprotiline—Vision blurred—Capecitabine—kidney cancer	0.000147	0.000607	CcSEcCtD
Maprotiline—Vomiting—Sunitinib—kidney cancer	0.000147	0.000606	CcSEcCtD
Maprotiline—Body temperature increased—Gemcitabine—kidney cancer	0.000147	0.000605	CcSEcCtD
Maprotiline—Tremor—Capecitabine—kidney cancer	0.000146	0.000604	CcSEcCtD
Maprotiline—Rash—Sunitinib—kidney cancer	0.000146	0.000601	CcSEcCtD
Maprotiline—Dermatitis—Sunitinib—kidney cancer	0.000146	0.000601	CcSEcCtD
Maprotiline—Hypotension—Paclitaxel—kidney cancer	0.000145	0.000599	CcSEcCtD
Maprotiline—Headache—Sunitinib—kidney cancer	0.000145	0.000598	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—kidney cancer	0.000145	0.000596	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—kidney cancer	0.000143	0.00059	CcSEcCtD
Maprotiline—Nausea—Sorafenib—kidney cancer	0.000143	0.000589	CcSEcCtD
Maprotiline—Insomnia—Paclitaxel—kidney cancer	0.000141	0.00058	CcSEcCtD
Maprotiline—Asthenia—Vincristine—kidney cancer	0.00014	0.000579	CcSEcCtD
Maprotiline—Syncope—Capecitabine—kidney cancer	0.00014	0.000578	CcSEcCtD
Maprotiline—Leukopenia—Capecitabine—kidney cancer	0.00014	0.000577	CcSEcCtD
Maprotiline—Paraesthesia—Paclitaxel—kidney cancer	0.00014	0.000575	CcSEcCtD
Maprotiline—Vomiting—Dactinomycin—kidney cancer	0.000139	0.000574	CcSEcCtD
Maprotiline—Somnolence—Paclitaxel—kidney cancer	0.000138	0.00057	CcSEcCtD
Maprotiline—Palpitations—Capecitabine—kidney cancer	0.000138	0.000569	CcSEcCtD
Maprotiline—Rash—Dactinomycin—kidney cancer	0.000138	0.000569	CcSEcCtD
Maprotiline—Nausea—Sunitinib—kidney cancer	0.000137	0.000567	CcSEcCtD
Maprotiline—Loss of consciousness—Capecitabine—kidney cancer	0.000137	0.000566	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—kidney cancer	0.000137	0.000566	CcSEcCtD
Maprotiline—Dyspepsia—Paclitaxel—kidney cancer	0.000137	0.000564	CcSEcCtD
Maprotiline—Hypertension—Capecitabine—kidney cancer	0.000135	0.000556	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000134	0.000553	CcSEcCtD
Maprotiline—Fatigue—Paclitaxel—kidney cancer	0.000134	0.000552	CcSEcCtD
Maprotiline—Diarrhoea—Vincristine—kidney cancer	0.000134	0.000552	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—kidney cancer	0.000134	0.000551	CcSEcCtD
Maprotiline—Asthenia—Gemcitabine—kidney cancer	0.000133	0.000549	CcSEcCtD
Maprotiline—Constipation—Paclitaxel—kidney cancer	0.000133	0.000548	CcSEcCtD
Maprotiline—Anxiety—Capecitabine—kidney cancer	0.000133	0.000547	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000132	0.000545	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000132	0.000544	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—kidney cancer	0.000132	0.000542	CcSEcCtD
Maprotiline—Pruritus—Gemcitabine—kidney cancer	0.000131	0.000541	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—kidney cancer	0.000131	0.000539	CcSEcCtD
Maprotiline—Dry mouth—Capecitabine—kidney cancer	0.00013	0.000536	CcSEcCtD
Maprotiline—Nausea—Dactinomycin—kidney cancer	0.00013	0.000536	CcSEcCtD
Maprotiline—Dizziness—Vincristine—kidney cancer	0.000129	0.000534	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—kidney cancer	0.000129	0.000531	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—kidney cancer	0.000129	0.000531	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—kidney cancer	0.000129	0.000531	CcSEcCtD
Maprotiline—Confusional state—Capecitabine—kidney cancer	0.000129	0.00053	CcSEcCtD
Maprotiline—Feeling abnormal—Paclitaxel—kidney cancer	0.000128	0.000528	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000128	0.000527	CcSEcCtD
Maprotiline—Oedema—Capecitabine—kidney cancer	0.000128	0.000526	CcSEcCtD
Maprotiline—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000127	0.000524	CcSEcCtD
Maprotiline—Diarrhoea—Gemcitabine—kidney cancer	0.000127	0.000524	CcSEcCtD
Maprotiline—Infection—Capecitabine—kidney cancer	0.000127	0.000522	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000126	0.000521	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—kidney cancer	0.000126	0.000518	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—kidney cancer	0.000126	0.000518	CcSEcCtD
Maprotiline—Shock—Capecitabine—kidney cancer	0.000126	0.000517	CcSEcCtD
Maprotiline—Nervous system disorder—Capecitabine—kidney cancer	0.000125	0.000516	CcSEcCtD
Maprotiline—Thrombocytopenia—Capecitabine—kidney cancer	0.000125	0.000515	CcSEcCtD
Maprotiline—Tachycardia—Capecitabine—kidney cancer	0.000125	0.000513	CcSEcCtD
Maprotiline—Vomiting—Vincristine—kidney cancer	0.000124	0.000513	CcSEcCtD
Maprotiline—Skin disorder—Capecitabine—kidney cancer	0.000124	0.000511	CcSEcCtD
Maprotiline—Urticaria—Paclitaxel—kidney cancer	0.000124	0.000509	CcSEcCtD
Maprotiline—Rash—Vincristine—kidney cancer	0.000123	0.000509	CcSEcCtD
Maprotiline—Hyperhidrosis—Capecitabine—kidney cancer	0.000123	0.000508	CcSEcCtD
Maprotiline—Dermatitis—Vincristine—kidney cancer	0.000123	0.000508	CcSEcCtD
Maprotiline—Abdominal pain—Paclitaxel—kidney cancer	0.000123	0.000507	CcSEcCtD
Maprotiline—Body temperature increased—Paclitaxel—kidney cancer	0.000123	0.000507	CcSEcCtD
Maprotiline—Headache—Vincristine—kidney cancer	0.000123	0.000505	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000122	0.000503	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—kidney cancer	0.00012	0.000496	CcSEcCtD
Maprotiline—Hypotension—Capecitabine—kidney cancer	0.000119	0.000491	CcSEcCtD
Maprotiline—Vomiting—Gemcitabine—kidney cancer	0.000118	0.000487	CcSEcCtD
Maprotiline—Desipramine—ABCB1—kidney cancer	0.000118	0.0347	CrCbGaD
Maprotiline—Rash—Gemcitabine—kidney cancer	0.000117	0.000483	CcSEcCtD
Maprotiline—Dermatitis—Gemcitabine—kidney cancer	0.000117	0.000482	CcSEcCtD
Maprotiline—Headache—Gemcitabine—kidney cancer	0.000116	0.000479	CcSEcCtD
Maprotiline—Nausea—Vincristine—kidney cancer	0.000116	0.000479	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—kidney cancer	0.000116	0.000477	CcSEcCtD
Maprotiline—Insomnia—Capecitabine—kidney cancer	0.000115	0.000476	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—kidney cancer	0.000115	0.000475	CcSEcCtD
Maprotiline—Paraesthesia—Capecitabine—kidney cancer	0.000115	0.000472	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—kidney cancer	0.000114	0.000471	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—kidney cancer	0.000113	0.000468	CcSEcCtD
Maprotiline—Dyspepsia—Capecitabine—kidney cancer	0.000112	0.000463	CcSEcCtD
Maprotiline—Asthenia—Paclitaxel—kidney cancer	0.000112	0.00046	CcSEcCtD
Maprotiline—Nausea—Gemcitabine—kidney cancer	0.00011	0.000455	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00011	0.000454	CcSEcCtD
Maprotiline—Fatigue—Capecitabine—kidney cancer	0.00011	0.000453	CcSEcCtD
Maprotiline—Pruritus—Paclitaxel—kidney cancer	0.00011	0.000453	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—kidney cancer	0.000109	0.000451	CcSEcCtD
Maprotiline—Constipation—Capecitabine—kidney cancer	0.000109	0.00045	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—kidney cancer	0.000108	0.000446	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—kidney cancer	0.000108	0.000445	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—kidney cancer	0.000107	0.000443	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—kidney cancer	0.000107	0.000443	CcSEcCtD
Maprotiline—Diarrhoea—Paclitaxel—kidney cancer	0.000106	0.000438	CcSEcCtD
Maprotiline—Feeling abnormal—Capecitabine—kidney cancer	0.000105	0.000433	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—kidney cancer	0.000105	0.000433	CcSEcCtD
Maprotiline—Gastrointestinal pain—Capecitabine—kidney cancer	0.000104	0.00043	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—kidney cancer	0.000104	0.00043	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—kidney cancer	0.000103	0.000426	CcSEcCtD
Maprotiline—Dizziness—Paclitaxel—kidney cancer	0.000103	0.000424	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—kidney cancer	0.000102	0.000422	CcSEcCtD
Maprotiline—Urticaria—Capecitabine—kidney cancer	0.000101	0.000418	CcSEcCtD
Maprotiline—Abdominal pain—Capecitabine—kidney cancer	0.000101	0.000416	CcSEcCtD
Maprotiline—Body temperature increased—Capecitabine—kidney cancer	0.000101	0.000416	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—kidney cancer	0.000101	0.000415	CcSEcCtD
Maprotiline—Imipramine—ABCB1—kidney cancer	9.99e-05	0.0294	CrCbGaD
Maprotiline—Tension—Doxorubicin—kidney cancer	9.89e-05	0.000408	CcSEcCtD
Maprotiline—Vomiting—Paclitaxel—kidney cancer	9.89e-05	0.000407	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—kidney cancer	9.87e-05	0.000407	CcSEcCtD
Maprotiline—Rash—Paclitaxel—kidney cancer	9.8e-05	0.000404	CcSEcCtD
Maprotiline—Dermatitis—Paclitaxel—kidney cancer	9.79e-05	0.000404	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—kidney cancer	9.79e-05	0.000403	CcSEcCtD
Maprotiline—Headache—Paclitaxel—kidney cancer	9.74e-05	0.000401	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—kidney cancer	9.5e-05	0.000391	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—kidney cancer	9.26e-05	0.000382	CcSEcCtD
Maprotiline—Nausea—Paclitaxel—kidney cancer	9.23e-05	0.000381	CcSEcCtD
Maprotiline—Asthenia—Capecitabine—kidney cancer	9.15e-05	0.000377	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—kidney cancer	9.04e-05	0.000372	CcSEcCtD
Maprotiline—Pruritus—Capecitabine—kidney cancer	9.03e-05	0.000372	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—kidney cancer	9.02e-05	0.000372	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—kidney cancer	8.91e-05	0.000367	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—kidney cancer	8.86e-05	0.000365	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—kidney cancer	8.73e-05	0.00036	CcSEcCtD
Maprotiline—Diarrhoea—Capecitabine—kidney cancer	8.73e-05	0.00036	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—kidney cancer	8.7e-05	0.000359	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—kidney cancer	8.55e-05	0.000352	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	8.52e-05	0.000351	CcSEcCtD
Maprotiline—Dizziness—Capecitabine—kidney cancer	8.44e-05	0.000348	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—kidney cancer	8.39e-05	0.000346	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—kidney cancer	8.29e-05	0.000342	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—kidney cancer	8.22e-05	0.000339	CcSEcCtD
Maprotiline—Infection—Doxorubicin—kidney cancer	8.17e-05	0.000337	CcSEcCtD
Maprotiline—Vomiting—Capecitabine—kidney cancer	8.11e-05	0.000334	CcSEcCtD
Maprotiline—Shock—Doxorubicin—kidney cancer	8.09e-05	0.000333	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—kidney cancer	8.07e-05	0.000332	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—kidney cancer	8.05e-05	0.000332	CcSEcCtD
Maprotiline—Rash—Capecitabine—kidney cancer	8.04e-05	0.000332	CcSEcCtD
Maprotiline—Dermatitis—Capecitabine—kidney cancer	8.04e-05	0.000331	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—kidney cancer	8.03e-05	0.000331	CcSEcCtD
Maprotiline—Headache—Capecitabine—kidney cancer	7.99e-05	0.000329	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—kidney cancer	7.99e-05	0.000329	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—kidney cancer	7.95e-05	0.000328	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—kidney cancer	7.68e-05	0.000317	CcSEcCtD
Maprotiline—Nausea—Capecitabine—kidney cancer	7.58e-05	0.000312	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—kidney cancer	7.44e-05	0.000307	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—kidney cancer	7.38e-05	0.000304	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—kidney cancer	7.31e-05	0.000301	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—kidney cancer	7.24e-05	0.000298	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.1e-05	0.000293	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—kidney cancer	7.09e-05	0.000292	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—kidney cancer	7.03e-05	0.00029	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—kidney cancer	6.78e-05	0.000279	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—kidney cancer	6.73e-05	0.000277	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—kidney cancer	6.53e-05	0.000269	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—kidney cancer	6.5e-05	0.000268	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—kidney cancer	6.5e-05	0.000268	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—kidney cancer	5.9e-05	0.000243	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—kidney cancer	5.82e-05	0.00024	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—kidney cancer	5.63e-05	0.000232	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—kidney cancer	5.44e-05	0.000224	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—kidney cancer	5.23e-05	0.000216	CcSEcCtD
Maprotiline—Rash—Doxorubicin—kidney cancer	5.19e-05	0.000214	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—kidney cancer	5.18e-05	0.000214	CcSEcCtD
Maprotiline—Headache—Doxorubicin—kidney cancer	5.15e-05	0.000212	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—kidney cancer	4.89e-05	0.000201	CcSEcCtD
Maprotiline—HTR2A—Signaling Pathways—KDR—kidney cancer	5.55e-06	0.000128	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KDR—kidney cancer	5.54e-06	0.000127	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—BRAF—kidney cancer	5.53e-06	0.000127	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MTOR—kidney cancer	5.53e-06	0.000127	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KDR—kidney cancer	5.52e-06	0.000127	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KDR—kidney cancer	5.5e-06	0.000126	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CCND1—kidney cancer	5.48e-06	0.000126	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—JUN—kidney cancer	5.47e-06	0.000126	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KDR—kidney cancer	5.45e-06	0.000125	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CTNNB1—kidney cancer	5.43e-06	0.000125	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CDKN1B—kidney cancer	5.42e-06	0.000125	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—SLC2A1—kidney cancer	5.4e-06	0.000124	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	5.37e-06	0.000123	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTP1—kidney cancer	5.31e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL2—kidney cancer	5.31e-06	0.000122	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PTEN—kidney cancer	5.29e-06	0.000122	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.24e-06	0.00012	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KIT—kidney cancer	5.2e-06	0.000119	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—APC—kidney cancer	5.2e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CDKN1B—kidney cancer	5.19e-06	0.000119	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTM1—kidney cancer	5.18e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CCND1—kidney cancer	5.17e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—JUN—kidney cancer	5.16e-06	0.000119	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	5.13e-06	0.000118	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CTNNB1—kidney cancer	5.12e-06	0.000118	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KIT—kidney cancer	5.11e-06	0.000118	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—APC—kidney cancer	5.11e-06	0.000118	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KIT—kidney cancer	5.1e-06	0.000117	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—APC—kidney cancer	5.1e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—APC—kidney cancer	5.09e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KIT—kidney cancer	5.09e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL2—kidney cancer	5.08e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—APC—kidney cancer	5.07e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KIT—kidney cancer	5.07e-06	0.000117	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—KRAS—kidney cancer	5.07e-06	0.000116	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ABCB1—kidney cancer	5.03e-06	0.000116	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KIT—kidney cancer	5.02e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—APC—kidney cancer	5.02e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PTEN—kidney cancer	4.99e-06	0.000115	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—MAPK3—kidney cancer	4.98e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CCND1—kidney cancer	4.95e-06	0.000114	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—POMC—kidney cancer	4.95e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—JUN—kidney cancer	4.94e-06	0.000114	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP1A1—kidney cancer	4.91e-06	0.000113	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CTNNB1—kidney cancer	4.91e-06	0.000113	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	4.9e-06	0.000113	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—MAPK3—kidney cancer	4.89e-06	0.000112	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—BRAF—kidney cancer	4.88e-06	0.000112	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTM1—kidney cancer	4.88e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	4.87e-06	0.000112	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—POMC—kidney cancer	4.87e-06	0.000112	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—POMC—kidney cancer	4.86e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—MAPK3—kidney cancer	4.85e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—POMC—kidney cancer	4.84e-06	0.000111	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—POMC—kidney cancer	4.83e-06	0.000111	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—MAPK3—kidney cancer	4.81e-06	0.00011	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—BRAF—kidney cancer	4.81e-06	0.00011	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—BRAF—kidney cancer	4.8e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PTEN—kidney cancer	4.78e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—BRAF—kidney cancer	4.78e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—POMC—kidney cancer	4.78e-06	0.00011	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—VEGFA—kidney cancer	4.78e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—BRAF—kidney cancer	4.77e-06	0.00011	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—MAPK1—kidney cancer	4.74e-06	0.000109	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—BRAF—kidney cancer	4.72e-06	0.000108	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	4.66e-06	0.000107	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	4.66e-06	0.000107	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—MAPK1—kidney cancer	4.65e-06	0.000107	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	4.63e-06	0.000106	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CYP1A1—kidney cancer	4.63e-06	0.000106	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RAF1—kidney cancer	4.62e-06	0.000106	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—MAPK1—kidney cancer	4.62e-06	0.000106	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—kidney cancer	4.6e-06	0.000106	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RELA—kidney cancer	4.6e-06	0.000106	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—MAPK1—kidney cancer	4.57e-06	0.000105	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—ERBB2—kidney cancer	4.57e-06	0.000105	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.57e-06	0.000105	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	4.52e-06	0.000104	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MAPK3—kidney cancer	4.52e-06	0.000104	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MTOR—kidney cancer	4.51e-06	0.000104	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—kidney cancer	4.51e-06	0.000104	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTP1—kidney cancer	4.5e-06	0.000103	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—KRAS—kidney cancer	4.47e-06	0.000103	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.45e-06	0.000102	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	4.44e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	4.43e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—PIK3CA—kidney cancer	4.41e-06	0.000101	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—kidney cancer	4.4e-06	0.000101	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—kidney cancer	4.39e-06	0.000101	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—kidney cancer	4.39e-06	0.000101	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—kidney cancer	4.38e-06	0.000101	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—PIK3CA—kidney cancer	4.37e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—kidney cancer	4.36e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—kidney cancer	4.32e-06	9.93e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—kidney cancer	4.32e-06	9.93e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MAPK1—kidney cancer	4.3e-06	9.88e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MAPK3—kidney cancer	4.27e-06	9.81e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ABCB1—kidney cancer	4.26e-06	9.79e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	4.23e-06	9.73e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—kidney cancer	4.15e-06	9.54e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL2—kidney cancer	4.14e-06	9.52e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTM1—kidney cancer	4.14e-06	9.5e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	4.11e-06	9.44e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK3—kidney cancer	4.09e-06	9.39e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RAF1—kidney cancer	4.08e-06	9.37e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—kidney cancer	4.06e-06	9.33e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RELA—kidney cancer	4.06e-06	9.33e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MAPK1—kidney cancer	4.06e-06	9.33e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	4.04e-06	9.29e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—kidney cancer	4.04e-06	9.28e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—kidney cancer	4.03e-06	9.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	4.03e-06	9.27e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—JUN—kidney cancer	4.03e-06	9.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.02e-06	9.24e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—kidney cancer	4.01e-06	9.23e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RAF1—kidney cancer	4.01e-06	9.22e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	4.01e-06	9.21e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RAF1—kidney cancer	4e-06	9.2e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	4e-06	9.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RELA—kidney cancer	4e-06	9.18e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RAF1—kidney cancer	3.99e-06	9.17e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RELA—kidney cancer	3.99e-06	9.16e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MTOR—kidney cancer	3.98e-06	9.15e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RAF1—kidney cancer	3.98e-06	9.14e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—kidney cancer	3.97e-06	9.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RELA—kidney cancer	3.97e-06	9.13e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—kidney cancer	3.97e-06	9.12e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	3.97e-06	9.12e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—kidney cancer	3.96e-06	9.1e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RELA—kidney cancer	3.96e-06	9.1e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—kidney cancer	3.95e-06	9.07e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RAF1—kidney cancer	3.94e-06	9.05e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—kidney cancer	3.94e-06	9.05e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RELA—kidney cancer	3.92e-06	9.01e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.92e-06	9.01e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MTOR—kidney cancer	3.92e-06	9e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MTOR—kidney cancer	3.91e-06	8.98e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—kidney cancer	3.9e-06	8.96e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—kidney cancer	3.9e-06	8.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MTOR—kidney cancer	3.9e-06	8.96e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK1—kidney cancer	3.89e-06	8.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MTOR—kidney cancer	3.88e-06	8.93e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MTOR—kidney cancer	3.85e-06	8.84e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—kidney cancer	3.83e-06	8.81e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1B—kidney cancer	3.74e-06	8.59e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—kidney cancer	3.73e-06	8.57e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	3.68e-06	8.45e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—kidney cancer	3.67e-06	8.44e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1B—kidney cancer	3.67e-06	8.43e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—POMC—kidney cancer	3.66e-06	8.42e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	3.66e-06	8.4e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—kidney cancer	3.66e-06	8.4e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	3.65e-06	8.38e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	3.61e-06	8.3e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—kidney cancer	3.61e-06	8.29e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—kidney cancer	3.6e-06	8.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—kidney cancer	3.59e-06	8.25e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—kidney cancer	3.58e-06	8.22e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—kidney cancer	3.57e-06	8.2e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—kidney cancer	3.56e-06	8.19e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—JUN—kidney cancer	3.56e-06	8.17e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—kidney cancer	3.53e-06	8.12e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CTNNB1—kidney cancer	3.53e-06	8.11e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	3.52e-06	8.1e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—kidney cancer	3.52e-06	8.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—kidney cancer	3.51e-06	8.06e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—JUN—kidney cancer	3.5e-06	8.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—kidney cancer	3.5e-06	8.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—JUN—kidney cancer	3.49e-06	8.03e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—kidney cancer	3.49e-06	8.02e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—JUN—kidney cancer	3.48e-06	8e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—kidney cancer	3.48e-06	7.99e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	3.47e-06	7.98e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—JUN—kidney cancer	3.47e-06	7.98e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CTNNB1—kidney cancer	3.47e-06	7.97e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	3.45e-06	7.94e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—POMC—kidney cancer	3.45e-06	7.93e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—kidney cancer	3.44e-06	7.91e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	3.44e-06	7.91e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—kidney cancer	3.44e-06	7.91e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JUN—kidney cancer	3.44e-06	7.9e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	3.41e-06	7.84e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—kidney cancer	3.41e-06	7.83e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—kidney cancer	3.39e-06	7.78e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—kidney cancer	3.38e-06	7.76e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	3.37e-06	7.75e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—kidney cancer	3.37e-06	7.74e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—kidney cancer	3.36e-06	7.71e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK3—kidney cancer	3.33e-06	7.66e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—kidney cancer	3.32e-06	7.64e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—kidney cancer	3.26e-06	7.5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—kidney cancer	3.24e-06	7.45e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.22e-06	7.4e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK1—kidney cancer	3.17e-06	7.28e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—kidney cancer	3.11e-06	7.14e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—kidney cancer	3.06e-06	7.03e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—kidney cancer	3.05e-06	7.01e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.04e-06	6.99e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—kidney cancer	3.03e-06	6.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—kidney cancer	3e-06	6.9e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.99e-06	6.88e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK3—kidney cancer	2.94e-06	6.76e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—POMC—kidney cancer	2.92e-06	6.72e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—kidney cancer	2.92e-06	6.71e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.89e-06	6.65e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK3—kidney cancer	2.89e-06	6.63e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK3—kidney cancer	2.88e-06	6.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK3—kidney cancer	2.87e-06	6.59e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—kidney cancer	2.86e-06	6.57e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK3—kidney cancer	2.84e-06	6.53e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—kidney cancer	2.83e-06	6.51e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—kidney cancer	2.81e-06	6.47e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—kidney cancer	2.81e-06	6.45e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—kidney cancer	2.8e-06	6.43e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK1—kidney cancer	2.8e-06	6.43e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—kidney cancer	2.79e-06	6.41e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—kidney cancer	2.76e-06	6.35e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK1—kidney cancer	2.75e-06	6.33e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—kidney cancer	2.75e-06	6.32e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.75e-06	6.32e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK1—kidney cancer	2.75e-06	6.31e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK1—kidney cancer	2.74e-06	6.29e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK1—kidney cancer	2.73e-06	6.27e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK1—kidney cancer	2.7e-06	6.21e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—kidney cancer	2.66e-06	6.11e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—kidney cancer	2.64e-06	6.07e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—kidney cancer	2.6e-06	5.97e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—kidney cancer	2.59e-06	5.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—kidney cancer	2.59e-06	5.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—kidney cancer	2.58e-06	5.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—kidney cancer	2.55e-06	5.87e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—kidney cancer	2.55e-06	5.85e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—kidney cancer	2.43e-06	5.58e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—kidney cancer	2.4e-06	5.52e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	2.39e-06	5.49e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.38e-06	5.48e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.38e-06	5.46e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.37e-06	5.44e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—kidney cancer	2.35e-06	5.4e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	2.34e-06	5.39e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—kidney cancer	2.33e-06	5.36e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—kidney cancer	2.31e-06	5.31e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—kidney cancer	2.31e-06	5.3e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—kidney cancer	2.3e-06	5.28e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—kidney cancer	2.29e-06	5.26e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—kidney cancer	2.27e-06	5.21e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—kidney cancer	2.03e-06	4.67e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—kidney cancer	1.8e-06	4.13e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.69e-06	3.89e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.43e-06	3.3e-05	CbGpPWpGaD
